SynthesisRespiratory research & clinical practice2026
Hypoxia-pyroptosis-associated long noncoding RNAs as prognostic biomarkers in lung cancer: a systematic review and meta-analysis.
Synthesis in Respiratory research & clinical practice, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Objective: Hypoxia-pyroptosis-associated long noncoding RNAs (HP-lncRNAs) may contribute to cancer progression and treatment resistance, but their prognostic and mechanistic roles in lung cancer remain unclear. We conducted a systematic review and meta-analysis to evaluate their prognostic value and regulatory networks in lung cancer. Methods: Following Preferred Reporting Items for Systematic Reviews and Meta-Analyses guidelines, we systematically searched five scientific databases up to November 20, 2025, for studies evaluating HP-lncRNA expression and survival outcomes. Hazard ratios (HRs) were pooled by using random-effects models, with heterogeneity being assessed by I Results: A total of 27 studies were included, with 14 providing quantitative data for meta-analysis. High expression of HP-lncRNA signatures was significantly associated with poorer overall survival (pooled adjusted HR = 1.50; 95% CI, 1.23-1.84), with a pronounced effect in lung adenocarcinoma (adjusted HR = 1.64; 95% CI, 1.34-1.99). Subgroup analyses supported a consistent adverse association across cohort designs and showed that the association remained evident in the advanced-stage subgroup (adjusted HR = 1.60; 95% CI, 1.44-1.77), although clear stage-specific effect modification was not demonstrated. Mechanistic evidence linked some lncRNAs to hypoxia-related regulation and others to pyroptosis-related signaling. Although direct evidence of a single lncRNA connecting both pathways is limited, findings support possible hypoxia-pyroptosis crosstalk. HIF-1a and caspase-1 emerged as central hub genes. Conclusions: Our findings suggest that HP-lncRNA signatures may have prognostic relevance and therapeutic potential in lung cancer; however, the marked between-study heterogeneity indicates that further standardization and external validation are required before clinical application.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.